Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frederick Lansigan

Showing results (41-50 of 87) with videos related to

Pageof 9
Sort By:
Ejhaem|December 5, 2022
A phase I trial of BNC105P and ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemiaDarcy B Pooler, Dylan B Ness, Alexey V Danilov, et al.
Journal of Cutaneous Pathology|July 16, 2022
Primary cutaneous gamma-delta T-cell lymphoma masquerading as leukemia cutis in a patient recently diagnosed with small lymphocytic lymphoma: Clues to the diagnosisKoorosh Haghayeghi, Dhrumil Patel, Shauna M Rice, et al.
Leukemia Research Reports|June 18, 2021
Acute myeloid leukemia with hepatic infiltration presenting as obstructive jaundiceLandis R Walsh, Chaofan Yuan, James T Boothe, et al.
British Journal of Haematology|July 6, 2016
A phase I dose-ranging study of bendamustine and rituximab in chronic lymphocytic leukemia patients with comorbiditiesAlexey V Danilov, Lionel D Lewis, Frederick Lansigan, et al.
The American Journal of Occupational Therapy : Official Publication of the American Occupational Therapy Association|February 11, 2018
Goal Attainment and Goal Adjustment of Older Adults During Person-Directed Cancer RehabilitationKathleen Doyle Lyons, Robin M Newman, Peter A Kaufman, et al.
Journal of Cutaneous Pathology|March 8, 2018
Tumor-stage mycosis fungoides in palmoplantar localization with large-cell transformation and partial CD30 expression shows complete response to brentuximab vedotinAnh Khoa Pham, Joi B Carter, Nora R Ratcliffe, et al.
The American Journal of Surgical Pathology|May 29, 2026
TRBC1 Immunohistochemistry Utilization in Formalin-fixed Paraffin-embedded Tissue as an Adjunct to T-cell Clonality Testing in the Assessment of Cutaneous Lymphoproliferative DisordersDavid G Grand, Jeffrey M Cloutier, Sarah R Palmer-DeClara, et al.
Cancer Research Communications|August 31, 2023
A Survey of Cancer Risk Behaviors, Beliefs, and Social Drivers of Health in New Hampshire and VermontThomas A Skipper, Julie E Weiss, Heather A Carlos, et al.
Cancer Medicine|December 22, 2018
The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: A combined analysis of 3 CALGB trialsFrederick Lansigan, Ian Barak, Brandelyn Pitcher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 28, 2019
Multicenter, Open-Label, Phase II Study of Bendamustine and Rituximab Followed by 90-Yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma (Fol-BRITe)Frederick Lansigan, Cristiana A Costa, Bassem I Zaki, et al.
Pageof 9

Showing results (41-50 of 87) with videos related to

Sort By:
Pageof 9
Ejhaem|December 5, 2022
A phase I trial of BNC105P and ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemiaDarcy B Pooler, Dylan B Ness, Alexey V Danilov, et al.
Journal of Cutaneous Pathology|July 16, 2022
Primary cutaneous gamma-delta T-cell lymphoma masquerading as leukemia cutis in a patient recently diagnosed with small lymphocytic lymphoma: Clues to the diagnosisKoorosh Haghayeghi, Dhrumil Patel, Shauna M Rice, et al.
Leukemia Research Reports|June 18, 2021
Acute myeloid leukemia with hepatic infiltration presenting as obstructive jaundiceLandis R Walsh, Chaofan Yuan, James T Boothe, et al.
British Journal of Haematology|July 6, 2016
A phase I dose-ranging study of bendamustine and rituximab in chronic lymphocytic leukemia patients with comorbiditiesAlexey V Danilov, Lionel D Lewis, Frederick Lansigan, et al.
The American Journal of Occupational Therapy : Official Publication of the American Occupational Therapy Association|February 11, 2018
Goal Attainment and Goal Adjustment of Older Adults During Person-Directed Cancer RehabilitationKathleen Doyle Lyons, Robin M Newman, Peter A Kaufman, et al.
Journal of Cutaneous Pathology|March 8, 2018
Tumor-stage mycosis fungoides in palmoplantar localization with large-cell transformation and partial CD30 expression shows complete response to brentuximab vedotinAnh Khoa Pham, Joi B Carter, Nora R Ratcliffe, et al.
The American Journal of Surgical Pathology|May 29, 2026
TRBC1 Immunohistochemistry Utilization in Formalin-fixed Paraffin-embedded Tissue as an Adjunct to T-cell Clonality Testing in the Assessment of Cutaneous Lymphoproliferative DisordersDavid G Grand, Jeffrey M Cloutier, Sarah R Palmer-DeClara, et al.
Cancer Research Communications|August 31, 2023
A Survey of Cancer Risk Behaviors, Beliefs, and Social Drivers of Health in New Hampshire and VermontThomas A Skipper, Julie E Weiss, Heather A Carlos, et al.
Cancer Medicine|December 22, 2018
The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: A combined analysis of 3 CALGB trialsFrederick Lansigan, Ian Barak, Brandelyn Pitcher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 28, 2019
Multicenter, Open-Label, Phase II Study of Bendamustine and Rituximab Followed by 90-Yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma (Fol-BRITe)Frederick Lansigan, Cristiana A Costa, Bassem I Zaki, et al.
Pageof 9